Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
AstraZeneca and GKS shares have legs, but the weight loss titans will dominate, says investment bank
10:35am, Monday, 24'th Mar 2025
AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) remain among Berenberg's top picks in the pharmaceuticals sector, with the broker reaffirming its 'buy' rating on both stocks. The former ca
Forget the Correction: This Stock Is Defying the Sell-Off, and There Might Be More Upside Ahead
06:05am, Sunday, 23'rd Mar 2025
The tech-heavy Nasdaq Composite index recently entered correction territory. Though it was able to climb out of it, equities broadly remain down for the year.
AstraZeneca CEO on its $2.5 billion investment in Beijing hub
12:30pm, Friday, 21'st Mar 2025
British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in the Chinese capital.
Watch CNBC's full interview with AstraZeneca CEO Pascal Soriot
09:21am, Friday, 21'st Mar 2025
Pascal Soriot, CEO of British pharmaceutical giant AstraZeneca, discusses the company's $2.5 billion investment in a new China research and development center.
Watch CNBC's full interview with Pascal Soriot, AstraZeneca CEO
08:55am, Friday, 21'st Mar 2025
Pascal Soriot, CEO, AstraZeneca discusses the company's $2.5 billion investment in its new China research and development centre.
SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands , March 21, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and com
British pharma giant AstraZeneca to invest $2.5 billion in new China hub
07:10am, Friday, 21'st Mar 2025
British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in Beijing, China. Outside the Macclesfield factory of AstraZeneca.
AstraZeneca investing $2.5 bln in China as drugmaker seeks to recover from scandals
07:03am, Friday, 21'st Mar 2025
AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including
ANGLE passes key milestone as it completes AstraZeneca assay development
03:29am, Friday, 21'st Mar 2025
ANGLE PLC (AIM:AGL, OTCQX:ANPCY) has completed two major projects for AstraZeneca PLC (LSE:AZN), expanding the use of its Parsortix liquid biopsy system to support clinical trials in prostate and mul
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
07:20pm, Wednesday, 19'th Mar 2025
The latest trading day saw Astrazeneca (AZN) settling at $76.32, representing a -0.97% change from its previous close.
Mindpeak to deploy and evaluate AI-Powered Digital Pathology Risk Assessment Tools for Breast Cancer in collaboration with AstraZeneca
08:00am, Wednesday, 19'th Mar 2025
HAMBURG, Germany--(BUSINESS WIRE)--The collaboration aims to assess the transformative potential of AI in digital pathology, with a specific focus on accelerating primary breast cancer diagnosis. Brea
AZN's Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung Cancer
12:10pm, Monday, 17'th Mar 2025
The European Commission approves AstraZeneca's Imfinzi for treating patients with limited-stage small-cell lung cancer based on ADRIATIC study data.
AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies
10:40am, Monday, 17'th Mar 2025
AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or immune-mediated diseases.
IgniteData launches cutting edge data integration platform for clinical trials at Cambridge University Hospitals
08:04am, Monday, 17'th Mar 2025
CAMBRIDGE, United Kingdom , March 17, 2025 /PRNewswire/ -- IgniteData has announced a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) and Cambridge University Hospitals NHS Foundation Trust (CUH
AstraZeneca Buys EsoBiotec for Up to $1 Billion
03:47am, Monday, 17'th Mar 2025
The deal includes the Belgian biotech's vivo cell-therapy platform, which modifies immune cells within the patient's body, potentially increasing access to treatment and reducing costs.
